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Abstract
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) was first reported in December 2019. As similar cases rapidly emerged around the world1–3, the World
Health Organization (WHO) declared a public health emergency of international concern on January 30, 2020 and
pronounced the rapidly spreading coronavirus outbreak as a pandemic on March 11, 20204. The virus has reached
almost all countries of the globe. As of June 3, 2020, the accumulated confirmed cases reached 6,479,405 with more
than 383,013 deaths worldwide. The urgent and emergency care of COVID-19 patients calls for effective drugs, in
addition to the beneficial effects of remdesivir5, to control the disease and halt the pandemic.
US FDA approved hydroxychloroquine (HCQ) and
chloroquine (CQ) for COVID-19 as an Emergency Use
Authorization (EUA) with cautions issued soon after
On March 28, 2020, the U.S. Food and Drug Adminis-
tration (FDA) issued an EUA to allow hydroxy-
chloroquine sulfate and chloroquine phosphate donated
to the Strategic National Stockpile (SNS) to be distributed
and used for hospitalized COVID-19 patients. In fact,
these two drugs have been used for decades for the
therapy and control of malaria and autoimmune diseases.
In Peru, the bark extracts of cinchona tree was used to
treat malaria and babesiosis started almost 400 years ago.
About 200 years ago quinine was found to be the key anti-
malaria compound in the bark. The analog of quinine, CQ
was made in 1934 and formally introduced into clinical
practice in the United States in 1947 for the prophylactic
treatment of malaria. In addition, CQ was also used to
treat rheumatoid arthritis, and lupus erythematosus. A
safer derivative HCQ was made in 1955. In 2017, there
were more than five million prescriptions of HCQ in the
United States, indicating that in the absence of other drug
interactions or special health conditions, HCQ should be
a relatively safe drug.
Preliminary studies have suggested HCQ may have
utility in fighting COVID-196,7. Distinct possible effects
may be related to its function in the treatment of COVID-
19 patients: A. anti-virus, B. anti-inflammation, and C.
anti-thrombotic. As until now there have been no data
indicating HCQ has any immunity boosting effect, here
we will mainly discuss the anti-virus and anti-
inflammation effects. In in vitro assays, both CQ and
HCQ have been shown to possess antiviral activity against
various viruses, such as human immunodeficiency virus
(HIV), hepatitis A virus, hepatitis C virus, influenza A and
B viruses, influenza A H5N1 virus and others8. Recent
studies reported that CQ and HCQ could also inhibit
SARS-CoV-2 in vitro9,10, suggesting that they are poten-
tially applicable to COVID-19 patients. However, there is
to date no convincing report of the in vivo anti-viral
effects of HCQ/CQ11,12. Several randomized controlled
trials brought comforting news that CQ and HCQ showed
potential effects in reducing respiratory symptoms and
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pulmonary inflammation as evaluated by computed
tomography (CT) of COVID-19 patients13. Recently a
French non-randomized open-label trial revealed that on
day 6 the nasopharyngeal clearance of virus of the patients
receiving HCQ/azithromycin, HCQ only, and the control
group were 100%, 57.1%, and 12.5%, respectively14. In
view of this report, the USA government argued that
HCQ could be applied for treating COVID-19 and on
March 28, 2020, the use of CQ and HCQ in COVID-19
patients was permitted by the US FDA15 and advocated by
the Indian Council for Medical Research16, causing drug
companies to ramp up CQ and HCQ production. This led
to panic buying as people of attempted to acquire this
purported “life saving drug”. Even some physicians
stocked up CQ and HCQ for personal use in US and some
European countries17,18. However, initially a lack of
attention was paid to the risks of using CQ and HCQ19.
Accordingly, on April 24, 2020, FDA cautions against the
use of CQ/HCQ outside the hospital settings or a clinical
trials. In fact, one person in the U.S. died and another
became seriously ill after using verterinary formulation of
CQ tablets intended for use in fish tanks in an effort to
prevent COVID-19. Shortly after permitting the use of
CQ and HCQ for treating COVID-19, the US FDA issued
precautions on using these drugs. Hence, we believe that
serious discussions of the potential mechanisms are
urgently needed to guide the potential clinical application,
evaluation of efficacy and prevention of adverse effects of
these drugs.
HCQ exerts strong immunomodulatory effects
Despite widespread clinical use of CQ and HCQ in the
treatment of inflammatory rheumatic diseases and virus
infection, the underlying therapeutic effects and cellular
mechanisms of these drugs remain largely unknown.
Various modes of action have been proposed to explain
the therapeutic and/or adverse effects of CQ and HCQ in
COVID-19 patients, although most of the evidence is
based on in vitro studies. CQ is a potent inhibitor of
autophagy20–23 and cell death24,25, affecting distinct cell
function26,27 and survival28,29, and its derivative HCQ30
has similar properties inhibiting autophagy. In vitro
experiments in tissue culture have shown that CQ and
HCQ can increase endosomal pH, prevent virus-cell
fusion, and interfere with glycosylation of the ACE2
receptor and thus the binding of the SARS-CoV-2 S
protein to ACE231 (Fig. 1). On the other hand, we have
proposed that the strong anti-inflammatory capacity of
CQ and HCQ, which prevents autoimmune flare-ups and
organ damages32, plays a more important role in con-
trolling SARS-CoV-2 infection. The possible mechanisms
of the anti-inflammatory effects of CQ and HCQ are
mainly related to preventing antigen processing and
interrupting molecular pathways involved in immune
activation, subsequently resulting in the reduction of pro-
inflammatory cytokine secretion33,34.
Various studies have shown that HCQ increases the
intracellular pH and inhibits lysosomal activity in antigen-
presenting cells (APCs), including plasmacytoid dendritic
cells (pDCs)35,36 and B cells37, and also blocks major
histocompatibility complex (MHC) class II-mediated
antigen presentation to CD4+ T cells, and thus prevents
the differentiation of these T cells (such as T follicular
helper cells)38. This also leads to a reduction in the pro-
duction of cytokines, such as tumor necrosis factor-alpha
(TNF-α), interleukin 6 (IL-6), granulocyte macrophage
colony-stimulating factor (GM-CSF), and IL-1β38,39. HCQ
can effectively reduce symptoms in systemic lupus ery-
themat osus (SLE) patients by suppressing pDCs to secret
pro-inflammatory cytokines induced by anti-dsDNA-
associated immune complexes40. CQ also has been
reported to block RNA-mediated TLR7 signal pathway
activation41,42. In addition to TLRs pathway, CQ and
HCQ also have effects on cyclic GMP-AMP (cGAMP)
synthase (cGAS) activity by inhibiting its binding to
cytosolic DNA, and thus down-regulating STING-
dependent transcription of type I IFNs through IFN reg-
ulatory factor 3 (IRF3), ultimately leading to a reduction
of type I IFN release43–45. Such mechanisms of CQ and
HCQ in preventing antigen processing and suppressing
inflammatory signaling pathways markedly reduced the
production of pro-inflammatory cytokines, such as TNF-
α, IL-6, and IFN-γ by mononuclear cells39, and IFN-α and
CCL4 by pDCs treated with RNA-containing immune
complexes46.
Not all the patients are suited for taking HCQ against
COVID-19
SARS-CoV-2 infection can be generally divided into
three stages: asymptomatic, mild, and severe3,47. During
the asymptomatic and early mild symptomatic stages, it is
Fig. 1 Hydroxychloroquine (HCQ) shows several potential effects
against COVID-19 disease. While HCQ is likely to have the ability to
control the CRS, suppress hyperactive immune responses and
subsequently promote tissue repair, which leads to significantly
improved severe symptoms in late-stage of COVID-19.
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believed that if specific adaptive immune responses are
developed, virus can be eliminated and disease will not
progress to the severe stage to develop acute respiratory
distress syndrome (ARDS)47. Therefore, boosting immune
responses in patients in the early-stage or mild stage of
infection is certainly the key to prevent progression to
severe disease. Although CQ and HCQ have been
reported to inhibit many viruses in vitro through either
preventing virus–cell fusion or interfering with virus
replication, the anti-viral activity of these agents has not
been proven in any virus in any model in vivo. Therefore,
the use of CQ or HCQ at early stages of disease may be
related to eventual alternative effects; still, it may impinge
on the production of type I IFN43–45 and the activation of
immune cells39,46, which in turn could influence the
development of the specific antiviral immunity.
Recent literature has pointed to the possibility that the
number of asymptomatic infected proportion of a popu-
lation may be larger than expected. Those asymptomatic
individuals release substantial amount of SARS-CoV-2
virus and spread widely. The mechanism underlining the
asymptomatic infection is unknown, however, if CQ or
HCQ is used to prevent COVID-19, there could be
undesirable consequences. Since CQ and HCQ could
suppress the innate as well as adaptive immunity, appli-
cation of these drugs when immunity is required may lead
to the appearance of symptoms and spreading the virus to
a larger population. The use of CQ or HCQ as prophylaxis
for COVID-19 and the anticorrelation of CQ/HCQ usage
in selected countries and COVID-19 morbidity are under
study48.
We have proposed that at the severe stage of SARS-
CoV-2 infection, inflammation is critical and leads to
tissue damage, especially in the lungs47. At this stage,
suppressing inflammation is likely to have therapeutic
benefits. We propose that the anti-inflammatory and
immunomodulatory effects of CQ and HCQ are the
mechanisms of therapeutic effects that may be seen in
COVID-19 patients at the severe stage. At this stage,
through unknown mechanisms, large amount of cytokines
are released and the patients develop cytokine release
syndrome (CRS), or cytokine storm, an uncontrolled
recruitment of immune cells and production of a unique
combination of cytokines often in absence of T cells.
These cytokines cause special type of ARDS within a very
short period of time, requiring intubation and mechanical
respiratory support47. This leads to severe damage to
tissues of lungs, kidneys, and heart, and eventually results
in a multiple organ dysfunction49. At this stage, CQ and
HCQ treatment may be beneficial to reduce massive
cytokine release by various immune cells through inter-
fering with antigen processing and suppressing TLRs and
cGAS-STING signaling. Such mechanisms provide sup-
port to the hypothesis that HCQ is likely to have the
ability to control the CRS, by suppressing hyperactive
immune responses and subsequently promoting tissue
repair in COVID-19 patients (Fig. 1). Therefore, owing to
the absence of solid evidence at this juncture, large scale,
randomized controlled trials are necessary to assess the
preventive and therapeutic effects of CQ and HCQ on
asymptomatic, mild, and severe patients with COVID-19
to validate this hypothesis.
Could HCQ and CQ have protective vascular effects in
COVID-19 patients?
Vascular complications, including endothelium damage
and vasculitis-like manifestations, are common traits in
severe COVID-19 patients. In some patients vessel
hyperplasia, vessel wall thickening, lumen stenosis
accompanied by focal hemorrhage and thrombosis have
been detected3. Conditions of severe vessel failure
aggravate organ ischemia, tissue edema, and overall
inflammation. This leads to the suggestion that SARS-
CoV-2 may have a direct effect on endothelial cells (ECs),
which also express ACE2 receptors. Such hypothesis is
supported by findings showing that SARS-CoV-2 can
indeed infect human blood vessel organoids50 and by
post-mortem histological analysis of COVID-19 patient’s
organs51 showing endothelitis and EC inflammatory cell
death. These findings provide a strong rationale for the
use of HCQ and CQ to alleviate these severe COVID-19
manifestations, since these drugs combine anti-inflam-
matory, anti-thrombosis21,52 and vascular protective
effects21 (Fig. 2). We have previously shown that CQ has
anti-angiogenic, tumor vessel normalizing properties in
murine models of melanoma, without inducing EC
death21. The EC effects induced by CQ included increased
vessel barrier function, which alleviated tumor hypoxia.
The vascular protective effects of HCQ and CQ, if vali-
dated, may be particularly relevant in patients with pre-
existing diseases associated to vascular damage, like e.g. in
diabetes, hypertension, and obesity.
HCQ is more suitable than CQ in treating COVID-19
HCQ and CQ are extremely similar in their structure
except for the addition of a hydroxyl group to the side
chain and β-hydroxylation of the N-ethyl substituent.
These modifications decrease HCQ toxicity while pre-
serving its efficacy53,54. HCQ is administered as a sulfate,
whereas CQ as a phosphate, and both of them are
absorbed in the upper intestinal tract. The half-lives of
CQ and HCQ are relatively long (960–1440 h) after
absorption, and both drugs are shown to distribute to
aqueous cellular and intercellular compartments, leading
to long mean residence duration (~900 h for CQ and
~1300 h for HCQ)55. In general, both drugs are well tol-
erated. However, several common adverse effects have
been reported in patients with long-term exposure to CQ
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and HCQ, such as gastrointestinal disorder, skin rash,
retinopathy, blurred vision, cardiac toxicity, and others56
The most serious toxicity of HCQ and CQ is retinopathy,
though it is rare, sight threatening may progress even to
loss of vision and it is generally irreversible57,58. Clinical
studies indicate that HCQ is associated with a lower risk
of retinopathy than CQ, which may be due to the lower
distribution volume as compared to CQ55. Another side
effect of concern is cardiotoxicity caused by both drugs.
Several researchers have reported cardiotoxic effects, such
as myopathy, arrhythmia, and conduction disorder59,60.
However, the exact evidence of cardiotoxicity caused by
these drugs is still unknown. Moreover, keratopathy
appears to occur more frequently in patients with CQ
than with HCQ61. In addition, CQ exerts a number of
severe side effects on fetal development, while HCQ can
be safely used in patients with SLE during pregnancy and
breastfeeding and provides protective effect for both
mother and child62. The outbreak of SARS-CoV-2 has
placed many pregnant women at high risk of infection
(several infected cases have been reported). HCQ, rather
than CQ, should be recommended as a more optimal
choice for those patients, given its safety profile in preg-
nant women. Another important issue is whether CQ and
HCQ are more toxic to COVID-19 patients is still a wide
open question that need to be addressed.
A cautionary note
However, recent observational studies in 1446 con-
secutive, non-randomized patients suggest that HCQ
administration was not associated with either a greatly
lowered or an increased risk of the composite end point of
intubation or death11. Still, HCQ-treated patients were
more severely ill at baseline than those who did not
receive HCQ. More, the toxic side effects were minimal.
In a retrospective multicenter cohort study in 25 different
hospitals on 1438 patients with distinct medications and
pre-existing conditions, there were no significant differ-
ences in mortality for patients receiving HCQ+ azi-
thromycin, HCQ alone, or azithromycin alone12. Another
manuscript reported similar conclusion63, even though a
serious “expression of concern” has been issued on this
report64. Therefore, proper randomized, controlled trials
of HCQ in patients with COVID-19 are needed. The
multifaceted actions of HCQ on several vital processes,
including autophagy and lysosomal function, which have
been proposed to be key organ repair mechanisms
essential to survive critical illness65, may ultimately
oppose its potential benefits. Additionally, cardiotoxicity
has been reported66,67. Also for this former paper, a ser-
ious “expression of concern” has been issued68. This still
calls for caution, since besides elucidating ‘what and how’
further insights into ‘when’ HCQ should be administered
need to be carefully examined. Therefore, further valida-
tion in randomized clinical trials is needed to establish
both the efficacy of HCQ or CQ in reducing the vascular
damage caused by SARS-CoV-2 and its therapeutic win-
dow in COVID-19 patients.
Conclusion
Taken together, given the fast-increasing number of
COVID-19 patients and the urgent need for effective and
safe drugs in the clinic, CQ and HCQ have potential, but
controversial, characteristics to combat pathological
inflammation associated with COVID-19. The recom-
mendation CQ and HCQ as a preventive medication for
healthy and asymptomatic infected persons48, even for
patients experiencing only mild symptoms in the early-
stage of SARS-CoV-2 infection because of the immuno-
suppressive effects of the two drugs will diminish specific
antiviral immunity, or as late stages therapeutic, still waits
a proper double blind clinical trial. However, HCQ has
been hypothesized to help controlling distinct effects of
SARS-CoV-2 infection, as described above and compared
Fig. 2 Speculative dual role exerted by HCQ/CQ on calming tissue inflammation and protecting the endothelium against SARS-CoV-2 mediated
injury.
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to CQ, HCQ confers similar antiviral and anti-
inflammatory effects while has fewer side effects, indi-
cating HCQ is a more optimal selection for treating
COVID-19. Importantly, when HCQ is used to treat
COVID-19 patients, individual immune profiles should be
thoroughly evaluated and considered. The above con-
sideration offers a clear rational for a systematic evalua-
tion of efficacy at the clinical level.
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